| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/18/2004 | US20040054145 Truncated cd200 |
| 03/18/2004 | US20040054140 Neuronal differentiation regulating factor for treatment of central nervous system disorders |
| 03/18/2004 | US20040054133 Multiple sclerosis-related superantigen |
| 03/18/2004 | US20040054005 Sodium channel blocker compositions and the use thereof |
| 03/18/2004 | US20040054001 For preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB, particularly psoriasis |
| 03/18/2004 | US20040053993 Compositions of tocol-soluble therapeutics |
| 03/18/2004 | US20040053982 Such as 3-(2-(6-methyl-pyridin-2-ylamino)-5-(1,2,4)triazol-1-yl-thiazol-4 -yl)benzonitrile for treatment of inflammatory or obstrucive airways diseases |
| 03/18/2004 | US20040053977 Such as N-pyridin-2-yl-N'-(1-pyridin-2-yl-ethylidene)hydrazine for increasing erythropoietin levels and vascularization of tissue; antihypoxic agents |
| 03/18/2004 | US20040053976 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 03/18/2004 | US20040053973 Substituted 1,3-thiazole compounds, their production and use |
| 03/18/2004 | US20040053965 N-type calcium channel antagonists for the treatment of pain |
| 03/18/2004 | US20040053963 Urotensin-II receptor antagonists |
| 03/18/2004 | US20040053957 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization |
| 03/18/2004 | US20040053956 Isoquinoline derivatives useful in the treatment of cns disorders |
| 03/18/2004 | US20040053953 Treatment of chemokine mediated diseases |
| 03/18/2004 | US20040053951 Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use |
| 03/18/2004 | US20040053947 Pyrrolo[2,3-D]pyrimidine compounds |
| 03/18/2004 | US20040053942 Fused pyrazole derivatives bieng protein kinase inhibitors |
| 03/18/2004 | US20040053941 Substituted pyrazine derivatives |
| 03/18/2004 | US20040053937 Pyrimidine compounds |
| 03/18/2004 | US20040053930 7-Chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain |
| 03/18/2004 | US20040053929 1, 2, 5, 10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain |
| 03/18/2004 | US20040053925 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use |
| 03/18/2004 | US20040053924 Reacting pyrrolo(2,3-d)pyrimidin-4-one derivative containing a leaving group with a aromatic or heteroaromatic amine, hydroxy, marcaptan etc. in presence of a polar solvent and a catalyst |
| 03/18/2004 | US20040053921 Compounds useful as reversible inhibitors of cysteine proteases |
| 03/18/2004 | US20040053920 Administering to a patient suffering from caspase mediated diseses, an effective amount of a mono,bi or tri-heterocyclic ring containing nitrogen atom attached to ester or thioester to form carbamate group, as caspase inhibitor |
| 03/18/2004 | US20040053917 Reacting cyanophenyl-4-sulfonylchloride with a piperidine-4-oxo in presence of ethylene glycol to form an intermediate, reducing cyano group, followed by amidation, then reacting with an amine to form sulfonamide end |
| 03/18/2004 | US20040053914 Substituted piperzino-pyridine compound, useful for treting pain, anxiety, urinary incontinence, an addictive disorder, Parkinson's disease, epilepsy, psychosis, and used as Selective antagonists of the metabotropic glutamate receptor 5 |
| 03/18/2004 | US20040053898 For organ specific therapy; for treatment of menopausal symptoms, hormone-deficiency diseases and neurodegenerative diseases |
| 03/18/2004 | US20040053890 Naphthalene derivatives |
| 03/18/2004 | US20040053877 Comprises Sendai virus (SeV) vector; analyzed using LacZ reporter gene and insulin-like growth factor; for treatment of neuromusclar disorders |
| 03/18/2004 | US20040053875 Comprises double-stranded RNA; extracted from HeLa cells |
| 03/18/2004 | US20040053869 Stem cell differentiation |
| 03/18/2004 | US20040053854 Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides |
| 03/18/2004 | US20040053853 Topiramate salts and compositions comprising and methods of making and using the same |
| 03/18/2004 | US20040053852 Preventing desensitization of receptors |
| 03/18/2004 | US20040053851 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 03/18/2004 | US20040053842 Cholesterol ester transfer protein inhibitors for use in treating atherosclerosis optionally in combination with other antihypertensive agents |
| 03/18/2004 | US20040053839 Modulating apoptosis in a cell by administration of an apoptosis-modulating effective amount of an agent which interferes with prion protein-bax interaction |
| 03/18/2004 | US20040053838 Measuring serum IGF-I and/or IGF-I binding protein levels after birth of patient to obtain IGF-I or IGF-I binding protein level and correlating said level with in utero baseline level based on gestational age matched mean levels |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053826 Uses of polypeptides |
| 03/18/2004 | US20040053817 Proinsulin C-peptide is present in an absorbable matrix of polyglycolide-lactide copolymers; antidiabetic agents |
| 03/18/2004 | US20040053357 Nucleic acid encoding kv10.1 a voltage-gated potassium channel from human brain |
| 03/18/2004 | US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 03/18/2004 | US20040053228 Apoptosis inhibitory polypeptides, gene and polynucleotide encoding it and compositions containing the same |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | DE10240735A1 Regulating human endostatin expression, e.g. for treating CNS disorders or tumors, using nitrogen monoxide signal cascade modulators |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2497979A1 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| 03/18/2004 | CA2497901A1 Furan or thiophene derivative and medicinal use thereof |
| 03/18/2004 | CA2497833A1 A method of modulating cellular activity and molecules for use therein |
| 03/18/2004 | CA2497824A1 Use of a sri and vitamin b6 for the treatment of neurological and mental disorders |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/18/2004 | CA2441469A1 Methods and compositions for treating alzheimer's disease |
| 03/17/2004 | EP1398377A1 Growth differentation Factor-7 |
| 03/17/2004 | EP1398372A1 Lipid phosphate phosphatases and uses thereof for treating neuronal diseases |
| 03/17/2004 | EP1398038A1 Botulinum toxin pharmaceutical compositions |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1397503A2 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore |
| 03/17/2004 | EP1397495A2 22437, a human sulfatase and uses therefor |
| 03/17/2004 | EP1397485A2 Cell populations for detecting neuronal targets and potential active ingredients |
| 03/17/2004 | EP1397484A2 Methods and products related to fgf dimerization |
| 03/17/2004 | EP1397385A2 Methods for treating disorders of the nervous and reproductive systems |
| 03/17/2004 | EP1397379A1 Adenosine derivative in polymorph i form |
| 03/17/2004 | EP1397378A1 Adenosine derivative in polymorph ii form |
| 03/17/2004 | EP1397374A2 Siglec inhibitors |
| 03/17/2004 | EP1397370A1 B-benzyloxyaspartate derivatives with amino group on benzene ring |
| 03/17/2004 | EP1397366A1 Novel ligand for nicotinic acetylcholine receptors useful in therapy |
| 03/17/2004 | EP1397365A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397361A1 Carboline derivatives as pdev inhibitors |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397358A1 Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/17/2004 | EP1397357A2 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 03/17/2004 | EP1397356A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397354A1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
| 03/17/2004 | EP1397351A1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| 03/17/2004 | EP1397172A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397170A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397161A2 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 03/17/2004 | EP1397152A1 Use of tripeptide gpe for treating or preventing symptoms of parkinson's disease |
| 03/17/2004 | EP1397150A2 Somatostatin agonists |
| 03/17/2004 | EP1397145A2 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders |
| 03/17/2004 | EP1397142A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 03/17/2004 | EP1397138A2 Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments |
| 03/17/2004 | EP1397137A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1397136A1 Heterocyclic beta-aminoacids and their use as anti-epileptogenic agents |
| 03/17/2004 | EP1397135A2 Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways |
| 03/17/2004 | EP1397129A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors |
| 03/17/2004 | EP1397128A1 Kappa opiate agonists for the treatment of bladder diseases |
| 03/17/2004 | EP1397127A1 Solid pharmaceutucal formulations comprising modafinil |
| 03/17/2004 | EP1397053A1 Oral composition comprising an extract from the bark of albizzia myriophylla |
| 03/17/2004 | EP1305318B1 Process for the preparation of 9-amino substituted 9,10-dihydropyrrolo [2,1-b] [1,3]benzothiazepines |
| 03/17/2004 | EP1246816B1 Substituted phenyl-piperazine derivatives, their preparation and use |
| 03/17/2004 | EP1246815B1 Phenylpiperazinyl derivatives |
| 03/17/2004 | EP1242406B1 Novel compounds |
| 03/17/2004 | EP1242364B1 Adamantane derivatives |